Ginkgo Bioworks Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands except share data)
| Three Months Ended March 31, 2024 | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensive(Loss) Income | TotalStockholders’Equity | |
| Balance as of December 31, 2023 | 50,032,873 | $5 | $6,386,191 | $(5,290,528) | $1,484 | $1,097,152 |
| Issuance of common stock upon exercise or vesting of equity awards | 454,756 | — | 529 | — | — | 529 |
| Settlement of contingent consideration | 24,657 | — | 1,877 | — | — | 1,877 |
| Issuance of common stock for asset acquisitions | 328,321 | — | 15,876 | — | — | 15,876 |
| Stock-based compensation expense | — | — | 40,782 | — | — | 40,782 |
| Other comprehensive loss | — | — | — | — | (3,035) | (3,035) |
| Net loss | — | — | — | (165,911) | — | (165,911) |
| Balance as of March 31, 2024 | 50,840,607 | $5 | $6,445,255 | $(5,456,439) | $(1,551) | $987,270 |
| Three Months Ended March 31, 2025 | ||||||
| Common Stock | ||||||
| Shares | Amount | AdditionalPaid-InCapital | Accumulated Deficit | AccumulatedOtherComprehensive(Loss) Income | TotalStockholders’Equity | |
| Balance as of December 31, 2024 | 54,365,785 | $5 | $6,555,416 | $(5,837,557) | $(1,806) | $716,058 |
| Issuance of common stock upon exercise or vesting of equity awards | 332,461 | — | — | — | — | — |
| Release of 18,265 common shares from escrow related to acquisition | — | — | 939 | — | — | 939 |
| Stock-based compensation expense | — | — | 20,431 | — | — | 20,431 |
| Other comprehensive income | — | — | — | — | 956 | 956 |
| Net loss | — | — | — | (90,957) | — | (90,957) |
| Balance as of March 31, 2025 | 54,698,246 | $5 | $6,576,786 | $(5,928,514) | $(850) | $647,427 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.